

1 **High content image analysis in routine diagnostic histopathology predicts outcomes**
2 **in HPV-associated oropharyngeal squamous cell carcinomas**

3 **Jonas Hue^{a, *}, Zaneta Valinciute^a, Selvam Thavaraj^a & Lorenzo Veschini^{a, *}**

4 ^a Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, United
5 Kingdom

6 * Corresponding authors at: Faculty of Dentistry, Oral and Craniofacial Sciences, King's
7 College London, Guy's Hospital, Great Maze Pond, London, SE1 1UL, United Kingdom (J.
8 Hue and L. Veschini).

9 *Email addresses:* jonas_hue@hotmail.com (J. Hue) and lorenzo.1.veschini@kcl.ac.uk (L.
10 Veschini).

11 Word count: 3247

12 **Conflict of Interest**

13 The authors have no conflicts of interest to declare.

14 **Abstract**

15 *Objective:* Routine haematoxylin and eosin (H&E) photomicrographs from human
16 papillomavirus-associated oropharyngeal squamous cell carcinomas (HPV+OpSCC) contain
17 a wealth of prognostic information. In this study, we set out to develop a high content image
18 analysis workflow to quantify features of H&E images from HPV+OpSCC patients to identify
19 prognostic features which can be used for prediction of patient outcomes.

20 *Methods:* We have developed a dedicated image analysis workflow using open-source
21 software, for single-cell segmentation and classification. This workflow was applied to a set
22 of 567 images from diagnostic H&E slides in a retrospective cohort of HPV+OpSCC patients
23 with favourable (n = 29) and unfavourable (n = 29) outcomes. Using our method, we have
24 identified 31 quantitative prognostic features which were quantified in each sample and used
25 to train a neural network model to predict patient outcomes. The model was validated by k-
26 fold cross-validation using 10 folds and a test set.

27 *Results:* Univariate and multivariate statistical analyses revealed significant differences
28 between the two patient outcome groups in 31 and 16 variables respectively ($P < 0.05$). The
29 neural network model had an overall accuracy of 78.8% and 77.7% in recognising
30 favourable and unfavourable prognosis patients when applied to the test set and k-fold
31 cross-validation respectively.

32 *Conclusion:* Our open-source H&E analysis workflow and model can predict HPV+OpSCC
33 outcomes with promising accuracy. Our work supports the use of machine learning in digital
34 pathology to exploit clinically relevant features in routine diagnostic pathology without
35 additional biomarkers.

36 **Keywords:** Human Papillomavirus, Oropharyngeal Squamous Cell Carcinoma,
37 Oropharyngeal Cancer, Oral And Maxillofacial Pathology, Head And Neck Cancer,
38 Computer-assisted Image Analysis, Machine Learning, Neural Network Models, Tumor
39 Microenvironment, Single-cell Analysis.

40 **Introduction**

41 The worldwide incidence of HPV-associated oropharyngeal squamous cell carcinoma
42 (HPV+OpSCC) has been steadily increasing over the past two decades and is projected to
43 continue to rise over the next twenty years^{1,2}. In parallel with the alarming incidence rise of
44 this disease, it is now established that HPV+OpSCCs have on average better survival
45 outcomes compared to site and stage-matched HPV negative counterparts³. The robust
46 evidence of more favourable outcomes in HPV+OpSCC has led to recent calls for treatment
47 de-escalation in this group of patients, with several clinical trials currently in progress⁴.
48 However, it is also recognised that not all HPV+OpSCC patients will benefit from treatment
49 de-escalation since a small but significant proportion of these tumours demonstrate disease
50 progression or recurrence similar to HPV-independent oropharyngeal squamous cell
51 carcinoma (HPV-OpSCC)⁵⁻⁷. Therefore, accurately predicting patients who will benefit from
52 treatment de-escalation is key to improving their quality of life while at the same time
53 ensuring optimal radical dose regimens in cases likely to progress or recur.

54 Several potential prognostic factors in HPV+OpSCC have recently been described, including
55 tumour cytomorphology^{8,9}, density¹⁰ and immunoprofile of tumour infiltrating lymphocytes
56 (TILs)¹¹, plasma cell¹² and macrophage infiltrates¹², as well as gene methylation¹³ and
57 genomic heterogeneity¹⁴. Evaluating these biomarkers is a promising strategy to select
58 patients for treatment de-escalation in clinical trials. However, evaluation of biomarkers often
59 requires complex laboratory testing and interpretation which is costly, lack widespread
60 availability and is overall beyond the scope of routine diagnostic histopathology services.

61 Furthermore, the reason for unfavourable clinical outcomes is likely to be multifactorial¹⁵ and
62 individual biomarkers could fail to fully capture this complexity. Accounting for multiple
63 variables including cytomorphology, intratumoural morphologic heterogeneity, together with
64 spatial relationships between cancer cells and the immune microenvironment are likely to
65 improve our ability to accurately identify patients with favourable prognosis. However,
66 dedicated tools and workflows are currently unavailable.

67 Within this context, we developed an automated workflow for quantitative high content image
68 analysis (HCA) of diagnostic haematoxylin and eosin (H&E)-stained sections of
69 HPV+OpSCC using open-source software with little computational requirements. We
70 measured TILs, stromal plasma cells, tumour nuclear features, morphological heterogeneity
71 of tumour cells and the spatial relationship between TILs and tumour cells. The overall aim
72 of the current study was to assess the value of HCA to identify potentially prognostic
73 features in routine H&E slides and to develop a neural network model based on our features
74 to predict outcomes in HPV+OpSCC patients.

75

76 **Patients and Methods**

77 *Patient Selection*

78 Cases were selected from a previously characterised cohort of 231 patients HPV+OpSCC
79 patients treated at Guy's & St Thomas' NHS Foundation Trust between January 2005 and
80 December 2017¹⁰. HPV positivity was defined as strong and diffuse nuclear and cytoplasmic
81 staining for p16 immunohistochemistry and diffuse or punctate signal by HPV DNA in-situ
82 hybridisation according to current guidelines¹⁶. All 29 patients with unfavourable outcomes
83 (UO), (defined as death from disease or local, regional, or distant recurrence within 5 years)
84 were identified and included in the current study. An additional 29 patients with favourable
85 outcomes (FO), (defined as disease-free at 5 years) were randomly selected using a random
86 number generator. All patients were anonymised prior to image acquisition and data
87 analysis. A further 15 patients for a workflow development group were randomly selected
88 from the remaining cohort after excluding the 58 UO and FO patients. This group was used
89 to develop the image analysis workflow to ensure the workflow was robust enough to handle
90 previously unseen images. All patient data was handled in compliance with the UK Data
91 Protection Act. The Outer North East London Research Ethics Committee of the National
92 Research Ethics Service gave ethical approval for this work.

93 *Image Acquisition*

94 Ten separate representative digital images from archival diagnostic H&E-stained slides were
95 acquired at 100x optical magnification for each patient. Where possible, each image
96 contained approximately 70% tumour and 30% stroma. All images were assessed by a
97 specialist head and neck pathologist and deemed representative of the overall diagnostic
98 slide. A total of 567 images were acquired across the 58 patients with some patients having
99 less than ten images due to the small biopsy size.

100 *Image Analysis*

101 A dedicated image analysis workflow was developed to segment and classify individual cells
102 and cell objects in the H&E sections (Fig 1A). See Table 1 for a summary of the software
103 used and their respective functions. To develop the image analysis workflow, 15 patients
104 were randomly selected after excluding the 58 aforementioned UO and FO patients.
105 Processing was automated with scripts in QuPath and macros in ImageJ (publicly available
106 on GitHub at <https://github.com/jonashue1/HPV-OpSCC-Machine-Learning>).

107 Image pre-processing was performed in ImageJ¹⁷ by applying an unsharp mask to all
108 images. ImageJ was also used to empirically increase the minimum pixel values for faded
109 slides from 7 patients in a supervised manner. All images were then exported to QuPath¹⁸
110 where machine learning (ML) was used to overcome the issue of stain variability of H&E
111 images with an artificial neural network pixel-classifier. The pixel-classifier identified pixels of
112 interest belonging to cells and cell objects for easier downstream object-based segmentation
113 (Fig 1A2). To further improve segmentation of nuclei, Stardist was utilised as an ImageJ
114 plugin employing a pre-trained model based on H&E images¹⁹ (Fig 1A3). Elaborated images
115 were obtained and imported directly to CellProfiler²⁰ for object-level segmentation (cells,
116 tumour nuclei and nucleoli, TILs, and plasma cells) (Fig 1A4). Finally, we used an ML-based
117 object classifier tool (CellProfiler Analyst²¹) to further discriminate cells of interest on the
118 basis of object measurements (Fig 1A5). The various cells are classified with this model and

119 quantified by CellProfiler. The cell classification was qualitatively reviewed by a specialist
120 head and neck pathologist (see Fig 1B for examples of the cell classification).
121 An index of stromal TILs (TIL index) was calculated to attempt to account for the variation of
122 tumour and stromal areas in each image.

$$TIL\ Index = No.\ of\ Stromal\ TILs \times \frac{Tumour\ Area}{Stromal\ Area}$$

123 Tumour nuclear features for texture, granularity and morphology were measured in
124 CellProfiler. The cohesiveness of the tumour was measured by the distance of each tumour
125 cell to their first and second closest neighbours. The number of neighbours each tumour cell
126 had was also quantified.

127 Intratumoural heterogeneity for nuclear morphological, textural and spatial features was
128 quantified by the spread of the data for each respective variable and taken as the variance of
129 the measurement per field of view. All measurements were exported to an SQLite database
130 and imported into R.

131 The image analysis workflow took under 50 hours to process 567 images from 58 patients,
132 making measurements of more than 800 000 individual tumour and stromal cells with a
133 standard 8GB RAM computer. This averaged a processing time of approximately 51.7
134 minutes per patient.

135 *Identifying Prognostic Features*

136 Statistical analysis was performed in R using univariate Wilcoxon's rank sum test and
137 multivariate logistic regression (LR) to identify variables that had a statistically significant
138 difference between patients with unfavourable and favourable outcomes. Statistical
139 significance was accepted at $P < 0.05$.

140 *Prognostic Model*

141 The prognostic features identified were used to train a neural network to predict patient
142 outcomes in our cohort of patients. The 567 images were split into a training and test set
143 with 80% (n = 457) and 20% (n = 110) of images respectively. The neural network was
144 designed with 4 hidden layers and 16, 8, 8 and 4 nodes in each respective layer. The model
145 was further validated with a k-fold cross validation using 10 folds.

146 **Results**

147 The clinicopathologic features of the patient cohort are summarised in Table 2.

148 *Image Analysis Workflow*

149 An image analysis workflow was successfully developed to segment and classify the various
150 cell types within each biopsy. Fig 1B shows examples of the workflow being used to quantify
151 various biopsy features.

152 *Statistical analysis of selected features reveals prognostic features*

153 Quantitative measurements of the variables considered in this study are summarised in
154 Table 3. Univariate analysis revealed that 31 variables (Fig 2) in our study were significantly
155 different in FO versus UO patients demonstrating the value of these factors for patient
156 stratification. TILs, regardless of tissue compartment, were more abundant in FO patients
157 than UO patients. Plasma cell counts were also higher in the FO group with a median of 65
158 (97.25) versus 27 (53.5). Form factor, eccentricity, compactness cell area and perimeter are
159 used to quantify cytomorphology. In general, FO patients had rounder and less eccentric
160 cells, while cell area was not significantly different between the two groups. FO patients also
161 had tumour cells packed closer to one another with shorter distances between their
162 neighbours. FO patients had higher values for various texture and granularity measurements
163 of tumour nuclei. Intratumoural heterogeneity was significantly greater in UO patients for
164 most measurements of texture, granularity, cytomorphology and spatial packing.

165 Overall, the heat map (Fig 2) reveals clustering of patients by outcomes. Two broad clusters
166 appear evident from the heat map with most of FO patients clustering at the top. In general,
167 these patients had a stronger immune infiltrate and low intratumoural heterogeneity. On the
168 other hand, UO patients clustered at the bottom, exhibiting generally low immune infiltrate
169 and higher intratumoural heterogeneity. Our analysis also reveals inter-tumour homogeneity
170 for various measurements in FO patients. Conversely, patients with UO have greater inter-
171 tumour heterogeneity. When these patients do not strictly follow trends, predicting their
172 outcomes becomes increasingly difficult. Taken individually, none of the variables were
173 predictive of the outcome as shown by the inter- and intratumoural variability. Therefore, we
174 proceeded to analyse our data through multivariate LR and machine learning tools.

175 *Multivariate analysis and machine learning predicts patient outcomes*

176 Results of the multivariate LR are summarised in Table 3. Fig 3A shows boxplots of selected
177 variables that were statistically significant on both univariate and multivariate analyses.

178 We trained a neural network (NN) to use all statistically significant variables to predict patient
179 outcomes. Fig 3B shows the NN applied to the test set of images and a clear split between
180 the UO and FO groups. The model had an overall accuracy of 78.76%. In predicting patients
181 with FO, it had a sensitivity of 72.13% and a specificity of 86.54%. The model had a Kappa
182 statistic of 0.579, indicating a good model considering the difficulty of the task²².

183 Furthermore, a k-fold cross-validation was used to validate the model using 10 folds. This
184 revealed similar results when the model was applied to the test set with an average overall
185 accuracy of 77.72% and Kappa statistic of 0.552. The average sensitivity and specificity for
186 the favourable outcome group was 77.17% and 78.12% respectively.

187

188 **Discussion**

189 Recent years have seen a growing number of calls to de-intensify treatment regimens for
190 HPV+OpSCC since the majority of these patients demonstrate better overall and disease-
191 specific survival compared to HPV-unrelated counterparts. However, a significant proportion
192 of patients with HPV+OpSCC still exhibit UO following radical treatment for whom de-
193 intensification would be inappropriate⁵. While various biomarkers have proposed to have
194 prognostic value in HPV+OpSCC, none of these have been validated for routine clinical
195 practice or are under investigation to stratify patients in de-escalation trials. Against this
196 background, routine diagnostic H&E sections contain a wealth of data which can be
197 exploited for prognostic purposes without the need for additional laboratory tests which may
198 be costly and delay the initiation of treatment. However, assessment of H&E features by
199 pathologists is challenging, subject to bias and lacks reproducibility. For example, in Fig 1C,
200 representative photomicrographs from patients with FO (C1) and UO (C2) show similar
201 histological features, illustrating the challenges of subjective prognostication, even to an
202 experienced pathologist. By contrast, HCA and various implementations of machine learning
203 algorithms have been successfully employed to evaluate histology images in cancers²³, but
204 these tools are currently unavailable for OpSCC. Therefore, in the present work we aimed at
205 building an automated tool to analyse large numbers of histological images accurately and
206 reproducibly, to demonstrate the value of our tool to detect and measure prognostic features,
207 and to predict patient outcomes in HPV+OpSCC.

208 Our work has identified various prognostic factors, some of which corroborates with
209 established findings in the literature while others are fairly novel. TILs have been shown to
210 be a prognostic factor in HPV+OpSCCs¹⁰. However, many studies employ a semi-
211 quantitative method of assessment with suboptimal inter-observer agreement and
212 reproducibility. A digital workflow is able to perform the exact same steps with each round of
213 analysis. Furthermore, such methods of assessment are time-consuming and labour-
214 intensive for the quantification of a single prognostic feature. Many patients exhibit a strong
215 immune infiltrate consisting of various immune cell types like plasma cells and TILs and this

216 complicates the current proposed methods of TIL quantification by estimating the area of
217 stroma covered by TILs²⁴. Furthermore, to our best knowledge, previous studies have not
218 investigated the prognostic value of TILs in different tissue compartments, stromal versus
219 intratumoural in HPV+OpSCC. Our various measurements of TILs have all shown to be
220 strong prognostic factors. The implementation of the TIL index to account for variation in
221 area of tumour to stroma resulted in a high statistical significance, improving our confidence
222 in the measurement of this variable as a prognostic feature.

223 We found that stromal plasma cells were increased in patients with FO. Few studies have
224 investigated the role of plasma cells in the stromal component of HPV+OpSCCs and many
225 studies choose to ignore this subset of immune cells. However, some recent work has
226 suggested plasma cells may exhibit resistance to radiotherapy over other B cells²⁵. This may
227 have an impact on the antigen-specific antibody response to the tumour but further studies
228 elucidating the biological role of plasma cells in HPV+OpSCCs are required. Another study
229 looking at a plasma cell marker, immunoglobulin J polypeptide (IGJ), found that patients with
230 higher IGJ had better disease-specific and overall survival¹². While none of these studies
231 directly quantify plasma cells in H&E slides, they are in agreement with the trends we have
232 observed, and we show an alternative method to quantify plasma cells as a prognostic
233 feature without the transcriptomics or flow cytometry used in these studies.

234 Our workflow has managed to automate the single-cell quantification of anisonucleosis and
235 nuclear pleomorphism from several morphological measurements of tumour nuclei.

236 Previously, Lewis and colleagues reported an association between cellular anaplasia and
237 UO in HPV+OpSCCs²⁶. Similarly, our results revealed patients with FO tended to have
238 rounder, less eccentric nuclei with smaller perimeters for the same area. Interestingly, while
239 the size of the nuclei was not significantly different between the two groups when measured
240 across thousands of nuclei, there was greater heterogeneity in the sizes of nuclei from UO
241 patients. This highlights the importance of intratumour heterogeneity as prognostic feature,
242 while the average of a measured variable may not be prognostic itself, the degree of spread

243 of the data within the quantified variable may be prognostic. UO patients had greater
244 intratumour heterogeneity in all 5 morphological measurements with 4 of them being
245 statistically significant by univariate analysis. To the best of our knowledge, quantification of
246 morphological intratumour heterogeneity has not been reported in the literature for
247 HPV+OpSCCs. This morphologic heterogeneity may represent an underlying genetic
248 heterogeneity in patients with UO, although further investigations are required to identify this
249 potential link.

250 A previous study by Ali and colleagues found that the spatial distribution and tumour nuclear
251 clustering was helpful in developing a predictive model of outcome in p16+ OpSCC
252 patients²⁷. Similarly, we found that tumour nuclei from FO patients clustered closer to one
253 another as evidenced by higher number of neighbours and shorter first and second
254 neighbour distances. Furthermore, this pattern of spatial distribution was more homogenous
255 across the tumour for these FO patients. In non-HPV head and neck cancer, Delides and
256 colleagues quantified the heterogeneity of spatial distribution of laryngeal carcinoma by
257 measuring fractal dimensions²⁸. Their work revealed that patients with poor outcomes had
258 neoplastic tissues that exhibited greater spatial irregularities.

259 Texture features quantified by image analysis have been used to prognosticate patients from
260 various cancer types. However, most studies measure textural features across the whole
261 image rather than within the individual nuclei, making it more difficult to elucidate their
262 biological significance. However, a study in breast cancer measured nuclear textural
263 features as a way to quantify DNA arrangement and found some texture measurements to
264 improve the prognostication of patients²⁹. Our study similarly found several texture and
265 granularity measurements within tumour nuclei to be prognostic and these features were
266 used to train our neural network model. Furthermore, we attempted to quantify distinct
267 nucleoli by searching for small, round objects within tumour nuclei. We found patients with
268 more nucleoli had better outcomes and as expected, these patients also had higher textural
269 and granularity values. This shows that while textural features can be difficult to interpret and

270 ascribe biological significance to, they may be used to measure visual and biologically
271 relevant features within tumour cells. The presence and size of nucleoli have been reported
272 to carry both favourable and unfavourable prognosis in different cancer types^{30,31}. Hence, we
273 interpret these findings with caution as it is currently not possible to determine the quality of
274 function of these nucleoli through image analysis alone.

275 Overall, our model captures all these features providing ground to build predictive statistical
276 models able to account for multiple prognostic features. Importantly, most of our selected
277 features have direct link with known biological counterparts, thus our HCA tools could be
278 used to develop new mechanistic hypotheses and computational models to complement and
279 enrich statistical inference. Nonetheless, none of these prognostic features are able to
280 predict patient outcomes on their own. There is significant inter-sample heterogeneity as
281 visualised in the heat map (Fig 2.) and despite the patients generally clustering by outcome,
282 they do not form groups that are easily separable. Hence, AI tools that take into account
283 multiple variables and large quantities of data are required to make accurate predictions of
284 patient prognoses. In this study, we have shown the usefulness of such tools and their ability
285 to achieve promising accuracies.

286 We show that the development of a predictive statistical model is possible by automated
287 quantification of routine H&E biopsies without staining for additional biomarkers or other
288 diagnostics. This is also done in a timely manner, avoiding delays to treatment initiation. The
289 entire workflow averaged under an hour of processing time per patient on a standard
290 computer, without the need to purchase dedicated computational resources. While we have
291 developed a workflow that does not require the additional time and cost involved in obtaining
292 whole-slide scans, our platform is also easily adaptable to analyse whole-slide scans which
293 might be advantageous in a diagnostic digital pathology service context. Such a workflow
294 using free-to-use, open-source software is easy to implement, without high financial barriers
295 to entry. This allows a digital pathology workflow to be implemented even in developing
296 countries to improve diagnostic capabilities.

297 **Conclusion**

298 In summary, we built a single-cell quantitative image analysis workflow to analyse
299 HPV+OpSCC H&E slides to identify prognostic factors and quantify their heterogeneity
300 within the tumour. We have shown that some of these measures are predictive in their own
301 right, and that their variance within a tumour can itself be prognostic and contribute strongly
302 to the accuracy of predictive models.

303 Our open-source high content analysis workflow on routine H&E slides and statistical
304 modelling can aid prognostication of HPV+OpSCCs with promising accuracy. Our work
305 supports the use of machine learning-powered high content analysis followed by statistical
306 modelling in digital pathology to exploit clinically relevant features in routine diagnostic
307 pathology without additional laboratory diagnostics.

308 **Acknowledgements**

309 This research did not receive any specific grant from funding agencies in the public,
310 commercial, or not-for-profit sectors.

311 **Declaration of Competing Interests**

312 The authors have no competing interests to declare.

313 **Figure Captions**

314 Figure 1. (A1-6) Overview of the image analysis workflow. H&E images (A1) analysed by
315 ML-aided software. QuPath (A2) for initial pixel-level classification. Stardist (A3) refined
316 nuclear segmentation for clustered objects. CellProfiler (A5). Neural network model to
317 predict outcomes (A6). (B) Example workflow outputs of tumour nuclei (B1), plasma cells
318 (B2), TILs (B3), nucleoli (B4) and tumour nuclear eccentricity (B5). (C) Example H&E images
319 from favourable (C1) and unfavourable (C2) outcome groups at 100x magnification. All scale
320 bars represent 150µm.

321 Figure 2. Heat map of all statistically significant variables using Euclidean distance and
322 hierarchical clustering by complete linkage. Patients are colour-coded based on outcome,
323 green representing favourable and magenta representing unfavourable outcomes
324 respectively.

325 Figure 3. (A) Boxplots of selected prognostic variables identified with the workflow. Values
326 have been normalised within a range of 0 to 1. (B) The probability of each image being from
327 an UO patient as predicted by the neural network model, arranged from lowest to highest
328 probability when applied to the test set.

329 Table 1. Software used in the workflow and their respective functions.

No.	Software	Purpose
1.	QuPath	Pixel-level classification with an artificial neural network pixel classifier in-built in QuPath
2.	ImageJ	Unsharp mask for all images. Increasing minimum pixel intensities for faded slides. Renaming images for CellProfiler metadata.
3.	Stardist	Convolutional neural network for segmentation of clustered cells
4.	CellProfiler	Object-level segmentation. Feature measurements for supervised machine learning in CellProfiler Analyst. Single-cell quantification and measurements for cytomorphology spatial distribution, texture and granularity features.
5.	CellProfiler Analyst	Supervised machine learning for classification of different cell types with a Fast Gentle Boosting algorithm.
6.	RStudio	Univariate and multivariate data analysis. Training and validation of the prognostic neural network model.

330

331

332

333

334

335

	Favourable outcome	Unfavourable outcome
Age (mean/range)	62 (48-80)	60 (47-78)
Sex	Male (n)	26
	Female (n)	23
Stage	I-II (n)	4
	III-IV (n)	2
	26	26

336 Table 2. Clinicopathologic features of the patient cohort.

337

338 Table 3. Univariate Wilcoxon's rank sum test and multivariable logistic regression analyses

339 for all 34 analysed variables compared between favourable and unfavourable outcome

340 groups. Statistical significance accepted at $P < 0.05$.

	Variable	Favourable Median	Favourable IQR	Unfavourable Median	Unfavourable IQR	Univariable Wilcoxon rank sum test <i>P</i>	Multivariable Logistic Regression <i>P</i>
Immune Cell	TIL Index	11.31	22.24	3.16	10.78	<0.001	0.0074
	Intratumour TILs (n)	24	38	9	22	<0.001	0.5075
	Stromal TILs (n)	35	71.5	11	43	<0.001	0.0037
	Total TILs (n)	62.5	114.75	25	64	<0.001	0.662
	Plasma Cells (n)	65	97.25	27	53.5	<0.001	0.0082
Texture & Granularity	Texture Correlation	0.1452	0.077	0.0998	0.0821	<0.001	0.279
	Texture Entropy	9.7	0.39	9.68	0.45	<0.001	0.0068
	Texture InfoMeas1	0.9957	0.0037	0.9951	0.0046	0.017	0.2359
	Granularity 7	4.76	3.91	3.89	3.77	0.002	0.0032
	Granularity 1	62.87	10.98	61.25	13.53	0.006	0.4221
Tumour Nuclear Morphology	Form Factor	0.841	0.031	0.809	0.089	<0.001	0.8471
	Compactness	1.21	0.06	1.28	0.2	<0.001	0.1878
	Eccentricity	0.718	0.039	0.733	0.043	<0.001	0.0018
	Perimeter (Px)	98.37	12.05	100.65	10.73	0.0052	0.0096
	Cell Area (Px)	643.02	190.29	658.77	189.53	0.0821	0.0631
Tumour Cell Spatial Distribution	Number of Neighbours	5.81	0.03	5.8	0.05	<0.001	0.2811
	1st Neighbour Distance (Px)	36.63	4.2	37.55	6.68	<0.001	<0.001
	2nd Neighbour Distance (Px)	47.37	6.91	49.16	11.05	<0.001	<0.001
Other Tumour Features	Tumour Cell Count	1449.5	474.75	1334	590.5	<0.001	0.0874
	Image Nucleoli	404.5	341.75	334	269	<0.001	0.3394
	Nucleoli Ratio	0.269	0.246	0.27	0.203	0.0311	0.4019
Intra-tumour Heterogeneity	Texture Correlation	0.449	0.141	0.399	0.205	<0.001	0.0232
	Texture Entropy	0.219	0.139	0.305	0.256	<0.001	0.9846
	Texture InfoMeas1	1.03E-02	2.12E-02	0.0158	0.03	0.0011	0.4841
	Granularity 7	0.0571	0.0894	0.032	0.1114	0.0016	0.0067
	Granularity 1	0.234	0.18	0.262	0.278	0.0791	0.0172
	Form Factor	0.147	0.202	0.343	0.432	<0.001	0.0091
	Compactness	0.0292	0.0442	0.078	0.1286	<0.001	0.9956
	Eccentricity	0.483	0.212	0.496	0.181	0.1735	0.1382
	Perimeter	0.129	0.088	0.186	0.221	<0.001	0.001
	Cell Area	0.187	0.175	0.207	0.19	0.0012	0.0089
	Number of Neighbours	0.334	0.195	0.414	0.31	<0.001	0.1339
	1st Neighbour Distance	0.0604	0.055	0.0745	0.0829	<0.001	0.046
	2nd Neighbour Distance	0.0516	0.0517	0.0615	0.0613	0.0056	0.1434

341 **References**


- 342 1. Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated
343 oropharyngeal cancer. *Oral Oncol.* 2014;50(5):380-386.
- 344 2. Zhang Y, Fakhry C, D'Souza G. Projected Association of Human
345 Papillomavirus Vaccination With Oropharynx Cancer Incidence in the US,
346 2020-2045. *JAMA Oncol.* 2021;7(10):e212907.
- 347 3. Liu HW, Li JT, Zhou YB, Hu Q, Zeng Y, Mohammadreza MM. Human
348 Papillomavirus as a Favorable Prognostic Factor in a Subset of Head and
349 Neck Squamous Cell Carcinomas: A Meta-Analysis. *J Med Virol.*
350 2017;89(4):710-725.
- 351 4. Golusinski P, Corry J, Poorten VV, et al. De-escalation studies in HPV-
352 positive oropharyngeal cancer: How should we proceed? *Oral Oncol.*
353 2021;123:105620.
- 354 5. Masterson L, Moualed D, Liu ZW, et al. De-escalation treatment protocols for
355 human papillomavirus-associated oropharyngeal squamous cell carcinoma: a
356 systematic review and meta-analysis of current clinical trials. *Eur J Cancer.*
357 2014;50(15):2636-2648.
- 358 6. Mirghani H, Blanchard P. Treatment de-escalation for HPV-driven
359 oropharyngeal cancer: Where do we stand? *Clin Transl Radiat Oncol.*
360 2018;8:4-11.
- 361 7. Gorphe P, Classe M, Ammari S, et al. Patterns of disease events and causes
362 of death in patients with HPV-positive versus HPV-negative oropharyngeal
363 carcinoma. *Radiother Oncol.* 2022;168:40-45.
- 364 8. Westra WH. The Morphologic Profile of HPV-Related Head and Neck
365 Squamous Carcinoma: Implications for Diagnosis, Prognosis, and Clinical
366 Management. *Head and Neck Pathology.* 2012;6(1):48-54.
- 367 9. Lewis JS, Jr., Scantlebury JB, Luo J, Thorstad WL. Tumor Cell Anaplasia and
368 Multinucleation Are Predictors of Disease Recurrence in Oropharyngeal
369 Squamous Cell Carcinoma, Including Among Just the Human Papillomavirus-
370 Related Cancers. *The American Journal of Surgical Pathology.* 2012;36(7).
- 371 10. Ruangritchankul K, Sandison A, Warburton F, et al. Clinical evaluation of
372 tumour-infiltrating lymphocytes as a prognostic factor in patients with human
373 papillomavirus-associated oropharyngeal squamous cell carcinoma.
374 *Histopathology.* 2019;75(1):146-150.
- 375 11. Wieland A, Patel MR, Cardenas MA, et al. Defining HPV-specific B cell
376 responses in patients with head and neck cancer. *Nature.*
377 2021;597(7875):274-278.
- 378 12. Gui S, O'Neill WQ, Teknos TN, Pan Q. Plasma cell marker, immunoglobulin J
379 polypeptide, predicts early disease-specific mortality in HPV+ HNSCC. *J*
380 *Immunother Cancer.* 2021;9(3).
- 381 13. Gougousis S, Mouchtaropoulou E, Besli I, Vrochidis P, Skoumpas I,
382 Constantinidis I. HPV-Related Oropharyngeal Cancer and Biomarkers Based
383 on Epigenetics and Microbiome Profile. *Front Cell Dev Biol.* 2020;8:625330.

- 384 14. Worsham MJ, Chen KM, Ghanem T, Stephen JK, Divine G. Epigenetic
385 modulation of signal transduction pathways in HPV-associated HNSCC.
386 *Otolaryngol Head Neck Surg.* 2013;149(3):409-416.
- 387 15. Wu S, Zhu W, Thompson P, Hannun YA. Evaluating intrinsic and non-intrinsic
388 cancer risk factors. *Nature Communications.* 2018;9(1):3490.
- 389 16. Excellence NIHaC. Cancer of the upper aerodigestive tract: assessment and
390 management in people aged 16 and over.
391 [https://www.nice.org.uk/guidance/ng36/chapter/Recommendations#hpvrelated-](https://www.nice.org.uk/guidance/ng36/chapter/Recommendations#hpvrelated-disease)
392 [disease](https://www.nice.org.uk/guidance/ng36/chapter/Recommendations#hpvrelated-disease). Published 2016. Updated 06 June 2018. Accessed.
- 393 17. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform
394 for biological-image analysis. *Nat Methods.* 2012;9(7):676-682.
- 395 18. Bankhead P, Loughrey MB, Fernandez JA, et al. QuPath: Open source
396 software for digital pathology image analysis. *Sci Rep.* 2017;7(1):16878.
- 397 19. Schmidt U, Weigert M, Broaddus C, Myers G. Cell Detection with Star-Convex
398 Polygons. 2018; Cham.
- 399 20. McQuin C, Goodman A, Chernyshev V, et al. CellProfiler 3.0: Next-generation
400 image processing for biology. *PLoS Biol.* 2018;16(7):e2005970.
- 401 21. Jones TR, Kang IH, Wheeler DB, et al. CellProfiler Analyst: data exploration
402 and analysis software for complex image-based screens. *BMC Bioinformatics.*
403 2008;9(1):482.
- 404 22. Fleiss JL CJ, Everitt BS. Large sample standard errors of kappa and weighted
405 kappa. *Psychological Bulletin.* 1969;72(5):323-327.
- 406 23. Echle A, Rindtorff NT, Brinker TJ, Luedde T, Pearson AT, Kather JN. Deep
407 learning in cancer pathology: a new generation of clinical biomarkers. *British*
408 *Journal of Cancer.* 2021;124(4):686-696.
- 409 24. Hendry S, Salgado R, Gevaert T, et al. Assessing Tumor-Infiltrating
410 Lymphocytes in Solid Tumors: A Practical Review for Pathologists and
411 Proposal for a Standardized Method from the International Immuno-Oncology
412 Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract
413 Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial
414 and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck,
415 Genitourinary Carcinomas, and Primary Brain Tumors. *Adv Anat Pathol.*
416 2017;24(6):311-335.
- 417 25. Kim SS, Shen S, Miyauchi S, et al. B Cells Improve Overall Survival in HPV-
418 Associated Squamous Cell Carcinomas and Are Activated by Radiation and
419 PD-1 Blockade. *Clinical Cancer Research.* 2020;26(13):3345.
- 420 26. Lewis JS, Jr., Scantlebury JB, Luo J, Thorstad WL. Tumor cell anaplasia and
421 multinucleation are predictors of disease recurrence in oropharyngeal
422 squamous cell carcinoma, including among just the human papillomavirus-
423 related cancers. *The American journal of surgical pathology.* 2012;36(7):1036-
424 1046.
- 425 27. Ali S, Lewis J, Madabhushi A. Spatially aware cell cluster(spACC1) graphs:
426 predicting outcome in oropharyngeal p16+ tumors. *Med Image Comput*
427 *Comput Assist Interv.* 2013;16(Pt 1):412-419.

- 428 28. Delides A, Panayiotides I, Alegakis A, et al. Fractal dimension as a prognostic
429 factor for laryngeal carcinoma. *Anticancer Res.* 2005;25(3b):2141-2144.
- 430 29. Axelrod DE, Miller NA, Lickley HL, et al. Effect of Quantitative Nuclear Image
431 Features on Recurrence of Ductal Carcinoma In Situ (DCIS) of the Breast.
432 *Cancer Informatics.* 2008;6:CIN.S401.
- 433 30. Orsolich I, Jurada D, Pullen N, Oren M, Eliopoulos AG, Volarevic S. The
434 relationship between the nucleolus and cancer: Current evidence and
435 emerging paradigms. *Seminars in Cancer Biology.* 2016;37-38:36-50.
- 436 31. Stępiński D. The nucleolus, an ally, and an enemy of cancer cells. *Histochem*
437 *Cell Biol.* 2018;150(6):607-629.
- 438

A


1. H&E




2. QuPath




3. Stardist
















4. CellProfiler



5. CellProfiler Analyst



6. Neural Network

**B****C**

Heat Map of Statistically Significant Variables



-2 0 2

